Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS
- 27 January 2004
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 62 (2) , 282-284
- https://doi.org/10.1212/wnl.62.2.282
Abstract
The authors report the outcome of 14 patients with severe multiple sclerosis treated with autologous hematopoietic stem cell transplantation (AHSCT) after a median follow-up period of 3 years. The 3-year actuarial probability of progression-free survival was 85.7% and that of disease activity-free survival was 46.4%. On MRI, no T1-enhanced lesions were detected after AHSCT. The mean change in T2 lesion volume from baseline to the third year was −20.2% and that of the corpus callosum area was −12.7%; 50% of this reduction was seen during the first year.Keywords
This publication has 10 references indexed in Scilit:
- July 9 HighlightsNeurology, 2002
- Hematopoietic stem cell transplantation for multiple sclerosisZeitschrift für Neurologie, 2002
- How Do We Educate Young People to Balance Carbohydrate Intake with Adjustments of Insulin?Hormone Research in Paediatrics, 2002
- Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MSNeurology, 2001
- MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MSNeurology, 2001
- Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring.Transplantation and Cellular Therapy, 2000
- Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot FoundationZeitschrift für Neurologie, 2000
- High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosisBone Marrow Transplantation, 2000
- Autologous Stem Cell Transplantation in Progressive Multiple Sclerosis—An Interim Analysis of EfficacyJournal of Clinical Immunology, 2000
- Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell TransplantationBlood, 1998